BioNTech and Pfizer Inc.’s COVID-19 vaccine candidate is the first to demonstrate it can protect most people from contracting symptomatic infections with the virus in a Phase 3 clinical trial — an announcement that puts the companies in the lead to bring to market the first COVID-19 vaccine in the U.S.